Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Breast Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 90 articles:
HTML format



Single Articles


    October 2025
  1. GIAQUINTO AN, Freedman RA, Newman LA, Jemal A, et al
    Lobular breast cancer statistics, 2025.
    Cancer. 2025;131:e70061.
    PubMed     Abstract available


  2. BOWER JE, Radin A, Ganz PA, Irwin MR, et al
    Inflammation and dimensions of fatigue in women with early stage breast cancer: A longitudinal examination.
    Cancer. 2025;131:e70038.
    PubMed     Abstract available


  3. ISLAMI F, Wiese D, Schafer EJ, Sung H, et al
    Stage-specific cancer survival in Black and White persons by urbanicity of county of residence, United States, 2015-2021.
    Cancer. 2025;131:e70073.
    PubMed     Abstract available


  4. RIBI K, Cole BF, Fleming GF, Walley BA, et al
    Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.
    Cancer. 2025;131:e70094.
    PubMed     Abstract available


  5. COLAES R, Schroyen G, Radwan A, Gavrila Laic RA, et al
    Unveiling the impact of chemotherapy in patients with breast cancer: A longitudinal study on peripheral inflammation, multimodal magnetic resonance imaging, and cognition.
    Cancer. 2025;131:e70095.
    PubMed     Abstract available


  6. SHAFFER KM, Daniel KE, Wiseman KP, Ritterband LM, et al
    Prospective associations between sleep quality and sexual satisfaction in distressed breast cancer survivors: Secondary analysis from the Apps Reaching Cancer Survivors randomized trial.
    Cancer. 2025;131:e70093.
    PubMed     Abstract available


  7. NIERENGARTEN MB
    Omission of postoperative radiotherapy considered in older patients with breast cancer.
    Cancer. 2025;131:e70077.
    PubMed    


    September 2025
  8. CHEN M, Lin Z, Chen X, Zhang J, et al
    Feasibility and accuracy of targeted axillary dissection by carbon tattooing in biopsy-proven node-positive breast cancer: A prospective study.
    Cancer. 2025;131:e70047.
    PubMed     Abstract available


    August 2025
  9. NIERENGARTEN MB
    Endocrine therapy may be warranted in patients with ER-low, early-stage breast cancer.
    Cancer. 2025;131:e70002.
    PubMed    



  10. Correction to Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial.
    Cancer. 2025;131:e70018.
    PubMed    


    July 2025
  11. FONTVIEILLE E, Jansana A, Peruchet-Noray L, Cordova R, et al
    Body mass index and breast cancer risk among postmenopausal women with and without cardiometabolic diseases: Findings from two prospective cohort studies in Europe.
    Cancer. 2025;131:e35911.
    PubMed     Abstract available


  12. ANDERSON BO
    Prognostic staging for advanced breast cancer: A biological reevaluation of de novo Stage IV metastatic disease.
    Cancer. 2025;131:e35975.
    PubMed    


  13. NIERENGARTEN MB
    Imlunestrant significantly improves PFS for patients with advanced breast cancer.
    Cancer. 2025;131:e35913.
    PubMed    


  14. NIERENGARTEN MB
    Sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer.
    Cancer. 2025;131:e35914.
    PubMed    


    June 2025
  15. FUMAGALLI IA, Warner ET, Llanos AAM, Quesenberry CP, et al
    Racial and ethnic variation in body composition and prognosis of nonmetastatic breast cancer.
    Cancer. 2025;131:e35926.
    PubMed     Abstract available


  16. WANIS KN, Mitchell MP, Giordano SH, Litton JK, et al
    Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers.
    Cancer. 2025;131:e35910.
    PubMed     Abstract available


  17. AUBUCHON KE, Galvan CJC, Duron Y, Sampayo I, et al
    Randomized trial of a community-based, culturally tailored intervention: High engagement among Latina breast cancer survivors.
    Cancer. 2025;131:e35842.
    PubMed     Abstract available


    May 2025
  18. LEE MS, Thomas SM, Louie AD, Rosenberger LH, et al
    Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer.
    Cancer. 2025;131:e35891.
    PubMed     Abstract available


  19. ZHANG H, Charlton BM, Schnarrs PW, Trentham-Dietz A, et al
    Mammography screening and risk factor prevalence by sexual identity: A comparison of two national surveys.
    Cancer. 2025;131:e35852.
    PubMed     Abstract available


  20. YEN TWF, Nattinger AB, Bickell NA, Schymura MJ, et al
    Does regionalization of initial breast cancer care delay time to surgery?
    Cancer. 2025;131:e35895.
    PubMed     Abstract available


  21. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    PubMed     Abstract available


  22. ZOPE M, Sullivan R, Gutnik L
    Fragmented care and misaligned incentives of stakeholders in breast cancer care for the uninsured in the United States.
    Cancer. 2025;131:e35878.
    PubMed     Abstract available


  23. PEARCE A, Carter S, Frazer HM, Houssami N, et al
    Implementing artificial intelligence in breast cancer screening: Women's preferences.
    Cancer. 2025;131:e35859.
    PubMed     Abstract available


  24. SIMON LH, Saviers-Steiger C, Dunston ER, Galyean P, et al
    Feasibility and acceptability of the Comprehensive Oncology Rehabilitation and Exercise (CORE) clinical workflow algorithm in patients with newly diagnosed stage I-III breast cancer who undergo surgery as first-line treatment.
    Cancer. 2025;131:e35798.
    PubMed     Abstract available


    April 2025
  25. ZEINOMAR N, Perlstein M, Qin B, Iyer HS, et al
    Associations between experiences of discrimination and quality of life in Black breast cancer survivors.
    Cancer. 2025;131:e35836.
    PubMed     Abstract available


  26. PALESH O, Braun SE, Truong T, Hong S, et al
    Natural trajectory subclasses of cognitive impairment in breast cancer patients experiencing insomnia.
    Cancer. 2025;131:e35816.
    PubMed     Abstract available


  27. NIERENGARTEN MB
    Longer progression-free survival with targeted therapy for patients with metastatic breast cancer.
    Cancer. 2025;131:e35790.
    PubMed    


  28. GRAFF SL, Tolaney SM, Hart LL, Razavi P, et al
    Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer.
    Cancer. 2025;131:e35817.
    PubMed     Abstract available


    March 2025
  29. RAYCHAUDHURI S, McLaughlin E, Pennell ML, Stefanick M, et al
    The relationship between cardiometabolic abnormalities and mortality in the Women's Health Initiative: A comparison of associations among women with cancer to women without cancer.
    Cancer. 2025;131:e35804.
    PubMed     Abstract available


  30. PATEL RB, Sheng T, Diniz MA, Sparano JA, et al
    Impact of race/ethnicity on MammaPrint genomic assay risk and prognosis in early breast cancer: A National Cancer Data Base analysis.
    Cancer. 2025;131:e35771.
    PubMed     Abstract available


    February 2025
  31. MAZOR M, Lin JJ, Smith C, Rosa WE, et al
    Community-engaged adaptation of ACCESS: A navigator-led early palliative care intervention for Black and Latina women with advanced breast cancer.
    Cancer. 2025;131:e35745.
    PubMed     Abstract available


  32. BAEKER BISPO J, Jemal A, Islami F
    Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression.
    Cancer. 2025;131:e35724.
    PubMed     Abstract available


  33. WAKS AG, Tarantino P, Chen EL, Freedman RA, et al
    Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010-2019.
    Cancer. 2025;131:e35729.
    PubMed     Abstract available


  34. MARCOTTE LM, Khor S, Reddy A, Morenz A, et al
    An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system.
    Cancer. 2025;131:e35734.
    PubMed     Abstract available


    January 2025
  35. REN W, Guo X, Liu Z, Wu Y, et al
    Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Cancer. 2025;131:e35712.
    PubMed     Abstract available


  36. RAJABIUN S, Cabral HJ, Chen CA, Lloyd-Travaglini C, et al
    Cost and activity analysis for a citywide patient navigation intervention to engage underserved patients in breast cancer treatment: Findings from the Translating Research Into Practice study.
    Cancer. 2025;131:e35671.
    PubMed     Abstract available


  37. PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al
    Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.
    Cancer. 2025;131:e35664.
    PubMed     Abstract available


  38. BONTEMPS-JONES JE, McCullough LE, Kirkland EG, Teras LR, et al
    Beyond Tuskegee: A contemporary qualitative assessment of barriers to research participation among Black women.
    Cancer. 2025;131:e35648.
    PubMed     Abstract available


  39. NORIEGA ESQUIVES BS, Moreno PI, Munoz E, Lad TE, et al
    Effects of a culturally tailored patient navigation program on unmet supportive care needs in Hispanic/Latino cancer survivors: A randomized controlled trial.
    Cancer. 2025;131:e35626.
    PubMed     Abstract available


  40. SHIN DS, Ryu JM, Lee SK, Yu J, et al
    Nonsentinel lymph node metastases in cases of micrometastasis detected by sentinel lymph node biopsy after neoadjuvant chemotherapy.
    Cancer. 2025;131:e35567.
    PubMed     Abstract available


  41. TAN NQP, Ma GX, Maxwell AE, Brown RL, et al
    The impact of a small-group mammography video discussion on promoting screening uptake among nonadherent Chinese American immigrant women: A randomized controlled trial.
    Cancer. 2025;131:e35524.
    PubMed     Abstract available


    December 2024
  42. FARLEY CR, Sakach E, Ridge N, Sacks R, et al
    Top advances of the year: Breast cancer.
    Cancer. 2024 Dec 10. doi: 10.1002/cncr.35669.
    PubMed    


  43. REESE JB, Lepore SJ, Sorice KA, Zimmaro LA, et al
    Efficacy of a couple-based intervention addressing sexual concerns for breast cancer survivors: Results of a randomized controlled trial.
    Cancer. 2024 Dec 8. doi: 10.1002/cncr.35685.
    PubMed     Abstract available


    November 2024
  44. YAROSH RA, Nichols HB, Wang Q, Hirschey R, et al
    Patient-reported persistent lymphedema and peripheral neuropathy among long-term breast cancer survivors in the Carolina Breast Cancer Study.
    Cancer. 2024 Nov 17. doi: 10.1002/cncr.35650.
    PubMed     Abstract available


  45. DESAI P, Zhou Y, Grenet J, Handelman SK, et al
    Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.
    Cancer. 2024;130:3879-3887.
    PubMed     Abstract available


    October 2024
  46. MUSLUMANOGLU M, Cabioglu N, Igci A, Karanlik H, et al
    Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35610.
    PubMed     Abstract available


  47. JOHNSON HM, Song J, Warneke CL, Martinez AL, et al
    Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy.
    Cancer. 2024 Oct 29. doi: 10.1002/cncr.35619.
    PubMed     Abstract available


  48. BRUNET J, Sharma S, Zadravec K, Taljaard M, et al
    Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE): A randomized controlled trial.
    Cancer. 2024 Oct 21. doi: 10.1002/cncr.35540.
    PubMed     Abstract available


  49. PECCATORI FA, Prosperi Porta R, Azim HA Jr
    Reproductive autonomy and breastfeeding in young breast cancer survivors.
    Cancer. 2024 Oct 18. doi: 10.1002/cncr.35602.
    PubMed    


  50. GARG N, Thorat MA
    A nomogram for predicting axillary node pathologic complete response-A necessary component of the path toward true axillary de-escalation but needs a clear definition of the research question and a robust study design.
    Cancer. 2024;130:3549-3550.
    PubMed    


  51. ZHENG QJ, Xu L, Fan ZQ
    Reply to "A nomogram for predicting axillary node pathologic complete response-A necessary component of the path toward true axillary de-escalation but needs a clear definition of the research question and a robust study design".
    Cancer. 2024;130:3551-3552.
    PubMed    


  52. TIN TIN S, Smith-Byrne K, Ferrari P, Rinaldi S, et al
    Alcohol intake and endogenous sex hormones in women: Meta-analysis of cohort studies and Mendelian randomization.
    Cancer. 2024;130:3375-3386.
    PubMed     Abstract available


  53. SHI KS, Han X, Star J, Zhao J, et al
    Association of health insurance coverage disruptions and breast and colorectal cancer screening.
    Cancer. 2024 Oct 1. doi: 10.1002/cncr.35584.
    PubMed     Abstract available


    September 2024
  54. SELLA T, Sorouri K, Rosenberg SM, Loucks M, et al
    Breastfeeding experiences among young breast cancer survivors: A survey study.
    Cancer. 2024 Sep 29. doi: 10.1002/cncr.35585.
    PubMed     Abstract available


  55. IYENGAR NM, Scott JM, Lee J, Lavery JA, et al
    Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial.
    Cancer. 2024 Sep 22. doi: 10.1002/cncr.35575.
    PubMed     Abstract available


  56. WANG X, Shang Y, Zhang J, Liu J, et al
    Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node-negative, human epidermal growth factor receptor 2-positive breast cancer: A Surveillance, Epidemiology, and End Results population-based study.
    Cancer. 2024 Sep 22. doi: 10.1002/cncr.35581.
    PubMed     Abstract available


  57. ELSHAFIE S, Trivedi R, Villa-Zapata LA, Tackett RL, et al
    Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta-analysis.
    Cancer. 2024 Sep 5. doi: 10.1002/cncr.35550.
    PubMed     Abstract available


  58. REINER AS, Knight JA, John EM, Lynch CF, et al
    Reply to "Critical analysis of Reiner et al.'s study on agreement of medical record abstraction and self-report of breast cancer treatment".
    Cancer. 2024 Sep 4. doi: 10.1002/cncr.35549.
    PubMed    


  59. WANG W, Li X, Wang Y
    Critical analysis of Reiner et al.'s study on agreement of medical record abstraction and self-report of breast cancer treatment.
    Cancer. 2024 Sep 4. doi: 10.1002/cncr.35544.
    PubMed    


  60. LI R, Hua M, Li J, Chen W, et al
    The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and/or pneumonitis: A systematic review and single-arm meta-analysis.
    Cancer. 2024;130:2968-2977.
    PubMed     Abstract available


  61. XU C, Chen Z, Xia Y, Shi Y, et al
    Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China.
    Cancer. 2024;130.
    PubMed     Abstract available


    August 2024

  62. Erratum to "Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China".
    Cancer. 2024 Aug 30. doi: 10.1002/cncr.35368.
    PubMed    


  63. PARK KU, Lipsitz S, Dominici LS, Lynce F, et al
    Generative artificial intelligence as a source of breast cancer information for patients: Proceed with caution.
    Cancer. 2024 Aug 30. doi: 10.1002/cncr.35521.
    PubMed     Abstract available


  64. PLICHTA JK, Thomas SM, Chanenchuk TC, Chan K, et al
    Comparison of incident breast cancer cases in the largest national US tumor registries.
    Cancer. 2024 Aug 18. doi: 10.1002/cncr.35525.
    PubMed     Abstract available


  65. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    PubMed     Abstract available


  66. NIERENGARTEN MB
    Inequities in breast cancer from prevention through supportive care.
    Cancer. 2024;130:2570.
    PubMed    


    July 2024
  67. ELGHAZALY H, Azim HA, Rugo HS, Cameron D, et al
    Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389.
    PubMed     Abstract available


    June 2024
  68. REINER AS, Knight JA, John EM, Lynch CF, et al
    Agreement of medical record abstraction and self-report of breast cancer treatment with an extended recall window.
    Cancer. 2024 Jun 28. doi: 10.1002/cncr.35459.
    PubMed     Abstract available


  69. LU W, Giobbie-Hurder A, Tanasijevic A, Kassis SB, et al
    Acupuncture for hot flashes in hormone receptor-positive breast cancer: A pooled analysis of individual patient data from parallel randomized trials.
    Cancer. 2024 Jun 24. doi: 10.1002/cncr.35374.
    PubMed     Abstract available


  70. CHUNG HC, Saada-Bouzid E, Longo F, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35387.
    PubMed     Abstract available


  71. DENT S, Tumlinson R, Guha A, Moore H, et al
    Breast cancer risk reduction: Beyond pharmacologic intervention.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35442.
    PubMed    


  72. SELMOUNI F, Bendahhou K, Sauvaget C, Abahssain H, et al
    Impact of CBE-based screening program on care pathway, stage at diagnosis, nature of treatment, and overall survival among breast cancer patients in Morocco.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35419.
    PubMed     Abstract available


    May 2024
  73. BELAU MH, Jung L, Maurer T, Obi N, et al
    Social relationships and their impact on health-related quality of life in a long-term breast cancer survivor cohort.
    Cancer. 2024 May 17. doi: 10.1002/cncr.35364.
    PubMed     Abstract available


  74. SCHETTINI F, Blondeaux E, Molinelli C, Bas R, et al
    Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
    Cancer. 2024 May 16. doi: 10.1002/cncr.35323.
    PubMed     Abstract available


  75. CHLEBOWSKI RT, Aragaki AK, Pan K, Simon MS, et al
    Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women's Health Initiative.
    Cancer. 2024 May 13. doi: 10.1002/cncr.35318.
    PubMed     Abstract available


  76. HOVHANNISYAN M, Zemankova P, Nehasil P, Matejkova K, et al
    Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction.
    Cancer. 2024 May 8. doi: 10.1002/cncr.35337.
    PubMed     Abstract available


  77. GUO H, Malone KE, Heckbert SR, Li CI, et al
    Statin use and risks of breast cancer recurrence and mortality.
    Cancer. 2024 May 6. doi: 10.1002/cncr.35362.
    PubMed     Abstract available


    April 2024
  78. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    PubMed    


  79. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    PubMed    


  80. BERNSTEIN-MOLHO R, Shhada NA, Laitman Y, Netzer I, et al
    Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed >/=50 years.
    Cancer. 2024 Apr 17. doi: 10.1002/cncr.35329.
    PubMed     Abstract available


  81. VANNIER AGL, Dhungana A, Zhao F, Chen N, et al
    Validation of the RSClin risk calculator in the National Cancer Data Base.
    Cancer. 2024;130:1210-1220.
    PubMed     Abstract available


  82. NIERENGARTEN MB
    Routine estradiol testing recommended for women at high risk of breast cancer.
    Cancer. 2024;130:1014.
    PubMed    


  83. NIERENGARTEN MB
    Cardiotoxicity of breast cancer drugs requires additional monitoring.
    Cancer. 2024;130:1013-1014.
    PubMed    


  84. DELEIRE T, Mitchell JM, De La Cruz L, Isaacs C, et al
    Nonclinical factors associated with the treatment of older women with newly diagnosed low-grade ductal carcinoma in situ.
    Cancer. 2024;130:1041-1051.
    PubMed     Abstract available


    March 2024
  85. WANG X, O'Regan RM
    Breast cancer therapy in China: Introducing the Special Collection.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35288.
    PubMed    


  86. NIERENGARTEN MB
    FDA approves capivasertib with fulvestrant for breast cancer.
    Cancer. 2024;130:835-836.
    PubMed    


  87. WU J, Wang W, Gao L, Shao X, et al
    Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Cancer. 2024 Mar 14. doi: 10.1002/cncr.35270.
    PubMed     Abstract available


  88. PUKLIN LS, Ferrucci LM, Harrigan M, McGowan C, et al
    Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35280.
    PubMed     Abstract available


  89. ZHENG Q, Yan H, He Y, Wang J, et al
    An ultrasound-based nomogram for predicting axillary node pathologic complete response after neoadjuvant chemotherapy in breast cancer: Modeling and external validation.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35248.
    PubMed     Abstract available


    February 2024
  90. HOU X, Li X, Han Y, Xu H, et al
    Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35261.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.